Claudia Valenzuela

List of Publications by Year
in descending order

54	1,146	516215 16	433756 31
papers	citations	h-index	g-index

62	62	62	1366
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respiratory Medicine,the, 2020, 8, 925-934.	5.2	198
2	Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1800230.	3.1	95
3	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	5.2	71
4	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine,the, 2019, 7, 771-779.	5.2	65
5	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. European Respiratory Journal, 2020, 55, 1901760.	3.1	61
6	Role of imaging in progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180073.	3.0	57
7	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respiratory Medicine,the, 2021, 9, 1065-1076.	5.2	55
8	Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 312.	1.4	44
9	Normativa sobre el tratamiento farmacolÃ³gico de la fibrosis pulmonar idiopÃ¡tica. Archivos De Bronconeumologia, 2017, 53, 263-269.	0.4	40
10	Variability in Global Prevalence of Interstitial Lung Disease. Frontiers in Medicine, 2021, 8, 751181.	1.2	37
11	Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. Chest, 2019, 156, 706-714.	0.4	33
12	Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. Respiratory Research, 2019, 20, 127.	1.4	29
13	Guidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis. Archivos De Bronconeumologia, 2017, 53, 263-269.	0.4	21
14	Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes. Orphanet Journal of Rare Diseases, 2019, 14, 82.	1.2	21
15	Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. Respiratory Research, 2020, 21, 7.	1.4	19
16	Long-term safety and efficacy of tobramycin in the management of cystic fibrosis. Therapeutics and Clinical Risk Management, 2015, 11, 407.	0.9	18
17	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	3.0	17
18	Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis. BMC Pulmonary Medicine, 2014, 14, 150.	0.8	16

#	Article	IF	Citations
19	Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in Madrid. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 184-187.	0.3	16
20	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.4	16
21	Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness. PLoS ONE, 2015, 10, e0132546.	1.1	15
22	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2019, 36, 232-243.	1.3	15
23	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15
24	Adalimumab-induced interstitial pneumonia in a patient with Crohnâ€™s disease. World Journal of Gastroenterology, 2015, 21, 2260-2262.	1.4	12
25	The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 51, 1702596.	3.1	12
26	Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Advances in Therapy, 2022, 39, 3392-3402.	1.3	12
27	Lymphangioleiomyomatosis Treatment With Sirolimus. Archivos De Bronconeumologia, 2011, 47, 470-472.	0.4	10
28	The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. European Respiratory Journal, 2021, 57, 2100079.	3.1	10
29	Study of breast cancer incidence in patients of lymphangioleiomyomatosis. Breast Cancer Research and Treatment, 2016, 156, 195-201.	1.1	9
30	The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1900539.	3.1	8
31	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. Frontiers in Medicine, 2021, 8, 699644.	1.2	8
32	Desaturations During 6-Minute Walk Test and Predicting Nocturnal Desaturations in Adult Subjects With Cystic Fibrosis. Respiratory Care, 2019, 64, 48-54.	0.8	7
33	Novedades diagnÃ³sticas y terapÃ©uticas en fibrosis pulmonar progresiva. Archivos De Bronconeumologia, 2022, , .	0.4	7
34	Burkholderia cepacia complex infection in an Adult Cystic Fibrosis unit in Madrid. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 649-654.	0.3	6
35	Diagnostic approach of fibrosing interstitial lung diseases of unknown origin. Presse Medicale, 2020, 49, 104021.	0.8	6
36	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2021, 38, 4040-4056.	1.3	6

#	Article	IF	Citations
37	Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. EMBO Molecular Medicine, 2021, 13, e13929.	3.3	6
38	Non-invasive Ventilation in an Elderly Population Admitted to a Respiratory Monitoring Unit: Causes, Complications and One-year Evolution. Archivos De Bronconeumologia, 2012, 48, 349-354.	0.4	5
39	Pulmonary Fibrosis in the Time of COVID-19. Archivos De Bronconeumologia, 2022, 58, 6-7.	0.4	4
40	Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue. Molecular Cancer Research, 2021, 19, 1840-1853.	1.5	3
41	Screening of interstitial lung disease in patients with rheumatoid arthritis: A systematic review. ReumatologÃa ClÃnica (English Edition), 2022, 18, 587-596.	0.2	3
42	Erratum to â€œGuidelines for the medical treatment of idiopathic pulmonary fibrosisâ€•<[Arch. Bronconeumol. 53 (2017) 263â€“269]>. Archivos De Bronconeumologia, 2017, 53, 657-658.	0.4	2
43	ActualizaciÃ³n en neumonÃa intersticial con caracterÃsticas autoinmunes. Archivos De Bronconeumologia, 2018, 54, 447-448.	0.4	2
44	Communicating with patients with IPF: can we do it better?. ERJ Open Research, 2022, 8, 00422-2021.	1.1	2
45	Patientsâ€™ and Healthcare Professionalsâ€™ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801Âmg Tablet Formulation: A Multinational Survey. Pulmonary Therapy, 2020, 6, 93-105.	1.1	1
46	Pharmacological management. , 0, , 196-217.		1
47	Pulmonary involvement in inflammatory myopathies. , 2019, , 68-89.		1
48	Enfermedad pulmonar intersticial rÃ¡pidamente progresiva sin afectaciÃ³n cutÃ¡nea asociada a anticuerpos anti-MDA5. Medicina ClÃnica, 2021, 156, 413-414.	0.3	0
49	Autoimmunity in the Study of Interstitial Lung Disease: Are Serological Test Enough?. Archivos De Bronconeumologia, 2021, , .	0.4	0
50	Pulmonary function tests in multisystem disorders: prejudices and pitfalls. , 2019, , 14-26.		0
51	Eosinphilic granulomatosis with polyangiitis. , 2019, , 188-209.		0
52	Evidence for shared genetic risk factors between lymphangioleiomyomatosis and pulmonary function. ERJ Open Research, 2022, 8, 00375-2021.	1.1	0
53	[Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis. Archivos De Bronconeumologia, 2022, , .	0.4	0
54	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies.. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.4	0